Autophagy modulation: a target for cancer treatment development

Area of Science:

• Cellular Biology
• Oncology
• Pharmacology

Background:

• Autophagy is crucial for cellular homeostasis, preventing oncogenic development and clearing cellular debris.
• Dysregulation of autophagy is frequently observed in various cancers, complicating current treatment strategies.
• Modulating autophagy presents a novel therapeutic avenue for cancer treatment and overcoming drug resistance.

Purpose of the Study:

• To review current methods for modulating autophagy to prevent cancer.
• To evaluate strategies for overcoming anticancer therapy resistance by targeting autophagy.
• To assess the role of autophagy in various cancer types and its therapeutic potential.

Main Methods:

• A comprehensive literature search of PubMed and ClinicalTrials.gov was conducted.
• Keywords included "autophagy," "hydroxychloroquine," "chloroquine," and "cell death."
• Studies reviewed encompassed preclinical and clinical investigations of autophagy-modulating pathways and compounds.

Main Results:

• Autophagy pathways are prevalent in diverse cancers like leukemia, melanoma, and lung cancer.
• Autophagy-modulating compounds include inducers (e.g., everolimus) and inhibitors (e.g., hydroxychloroquine, chloroquine).
• Ongoing clinical trials (32 total) are investigating autophagy modulators, with early evidence suggesting efficacy in resistant cancers.

Conclusions:

• Preclinical data strongly support autophagy modulation as a promising strategy to enhance anticancer treatments.
• Targeting autophagy offers a novel approach to overcome challenges like chemotherapy resistance.
• Further research, including larger phase III trials, is needed to fully elucidate the therapeutic benefits of autophagy inhibitors.